KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor therapeutic outcomes.
• While KRAS mutations are key drivers, targeting them directly remains challenging.
• Existing therapies often face limitations due to acquired resistance and activation of parallel oncogenic pathways.

Approach:

• Review of cellular and preclinical studies focusing on KRAS-driven signaling pathways (RAS-RAF-MEK-ERK).
• Exploration of intersecting pathways, including PI3K/AKT/mTOR, implicated in PDAC resistance.
• Emphasis on mechanistic insights to understand pathway crosstalk and therapeutic vulnerabilities.

Key Points:

• Targeting the RAS-RAF-MEK-ERK cascade has shown potential for improving PDAC treatment responses.
• Concurrent activation of PI3K/AKT/mTOR signaling contributes to therapeutic resistance and reduced drug efficacy.
• Understanding the interplay between KRAS-downstream effectors and other oncogenic pathways is essential.

Conclusions:

• Developing novel therapeutic strategies requires a comprehensive understanding of overlapping signaling networks in PDAC.
• Combined approaches targeting both KRAS-dependent and -independent pathways may enhance treatment effectiveness.
• Further research into mechanistic insights is critical for overcoming PDAC tumor resistance.